Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

PURPOSE: Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for advanced MCC (aMCC) demonstrate increased progression-free survival (PFS) compared with historical chemotherapy data. Howe...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Nghiem, Paul, Bhatia, Shailender, Lipson, Evan J., Sharfman, William H., Kudchadkar, Ragini R., Brohl, Andrew S., Friedlander, Phillip A., Daud, Adil, Kluger, Harriet M., Reddy, Sunil A., Boulmay, Brian C., Riker, Adam I., Burgess, Melissa A., Hanks, Brent A., Olencki, Thomas, Margolin, Kim, Lundgren, Lisa M., Soni, Abha, Ramchurren, Nirasha, Church, Candice, Park, Song Y., Shinohara, Michi M., Salim, Bob, Taube, Janis M., Bird, Steven R., Ibrahim, Nageatte, Fling, Steven P., Homet Moreno, Blanca, Sharon, Elad, Cheever, Martin A., Topalian, Suzanne L.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2019
Sujets:
Rapid Communication
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6424137/
https://ncbi.nlm.nih.gov/pubmed/30726175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.01896
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires